L-3-n-Butylphthalide Protects HSPB8 K141N Mutation-Induced Oxidative Stress by Modulating the Mitochondrial Apoptotic

Xiao-Dong Yang1,2, Zhi-Dong Cen1, Hai-Peng Cheng3

  • 1Department of Neurology, The Second Affiliated Hospital, School of Medicine, Zhejiang UniversityHangzhou, China.

Insights

L-3-n-Butylphthalide (NBP) shows therapeutic potential for Charcot-Marie-Tooth disease type 2L (CMT2L). NBP reverses mitochondrial dysfunction and oxidative stress caused by HSPB8 K141N mutations, offering a promising treatment avenue.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Charcot-Marie-Tooth disease (CMT) is a common inherited peripheral nerve disorder.
  • Specific mutations in HSPB8, like K141N, cause CMT type 2L (CMT2L), a debilitating condition with limited therapeutic options.

Purpose of the Study:

  • To investigate the effects of the K141N HSPB8 mutation on mitochondrial function in a cellular model of CMT2L.
  • To evaluate the potential neuroprotective effects of L-3-n-Butylphthalide (NBP) against HSPB8 K141N-induced cellular damage.

Main Methods:

  • Utilized a cellular model expressing mutant K141N HSPB8.
  • Assessed mitochondrial distribution and function.
  • Investigated the impact of NBP on oxidative stress, apoptosis (Bax/Bcl-2 pathway), and Nrf2 signaling.

Main Results:

  • Mutant K141N HSPB8 induced mitochondrial aggregation and increased oxidative stress.
  • NBP treatment reversed these pathological changes.
  • NBP demonstrated antioxidant effects and modulated mitochondrial apoptotic and Nrf2 pathways.

Conclusions:

  • The K141N mutation in HSPB8 disrupts mitochondrial homeostasis and exacerbates oxidative stress.
  • NBP exhibits significant neuroprotective properties against CMT2L-associated cellular damage.
  • NBP presents a promising therapeutic candidate for treating Charcot-Marie-Tooth disease type 2L.